MODIFIED OLIGONUCLEOTIDES WHICH ACTIVATE RNASE H Russian patent published in 2021 - IPC C07H21/04 A61K31/7125 

FIELD: biotechnology.

SUBSTANCE: invention relates to biologically stable oligonucleotide derivatives with modified phosphate groups which can be used in pharmaceutical industry. Disclosed is a novel modified oligonucleotide with length of 5–21 nucleotides for binding with RNA and activation of RNase H, containing at least one group, corresponding to formula (III)

(III),

where B is a natural nitrogen base, R is a hydrogen atom, a nucleotide or oligonucleotide residue, R¹ is a hydrogen atom, a nucleotide or oligonucleotide residue, R² is independently selected from a group comprising C_1-6alkyl, p-methylphenyl, o-nitrophenyl, effective for in vitro binding with RNA and activation of RNase H, to produce a therapeutic agent, aimed at selective suppression of expression of undesired genes by binding with RNA and its hydrolytic cleavage through activation of RNase H cell enzyme.

EFFECT: disclosed are modified oligonucleotides which activate RNase H.

7 cl, 35 ex, 36 dwg